Literature DB >> 22638981

[Botulinum toxin in focal hyperhidrosis. An update].

C Hosp1, M K Naumann, H Hamm.   

Abstract

Eight years after its approval, intralesional injections of botulinum toxin type A have become established as an easily performed, highly effective and almost complication-free therapeutic option in primary axillary hyperhidrosis. Sweat production is decreased to about a sixth of previous amounts, and the effect persists for 7 months on average. Restoration of the often significantly impaired quality of life has been convincingly documented in large studies. The effect of botulinum toxin is based on the inhibition of the release of acetylcholine into the synaptic cleft. In addition to this approved use, botulinum toxin is also successfully employed in other forms of focal hyperhidrosis, particularly in gustatory sweating. However, its use in palmoplantar hyperhidrosis, the second most common form of primary hyperhidrosis, is limited because of the pain from numerous injections, need for increased doses of the expensive toxin and the relatively short effective period of about 4 months. Botulinum toxin type B appears to be comparably effective as type A products but is more often associated with systemic adverse events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22638981     DOI: 10.1007/s00105-012-2333-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  26 in total

1.  [Botulinum toxin treatment of eccrine sweat gland nevus].

Authors:  M Sonntag; L Rauch; T Ruzicka; D Bruch-Gerharz
Journal:  Hautarzt       Date:  2005-04       Impact factor: 0.751

2.  Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up.

Authors:  H Naver; C Swartling; S M Aquilonius
Journal:  Eur J Neurol       Date:  2000-01       Impact factor: 6.089

3.  Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.

Authors:  Leslie Baumann; Anele Slezinger; Monica Halem; Justin Vujevich; Lucy K Martin; Laura Black; Joy Bryde
Journal:  Int J Dermatol       Date:  2005-05       Impact factor: 2.736

4.  Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.

Authors:  Leslie Baumann; Anele Slezinger; Monica Halem; Justin Vujevich; Karin Mallin; Carlos Charles; Lucy K Martin; Laura Black; Joy Bryde
Journal:  Dermatol Surg       Date:  2005-03       Impact factor: 3.398

5.  Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.

Authors:  Nicholas J Lowe; Dee Anna Glaser; Nina Eadie; Simon Daggett; Jonathan W Kowalski; Pan-Yu Lai
Journal:  J Am Acad Dermatol       Date:  2007-02-15       Impact factor: 11.527

6.  Therapeutic effectiveness of botulinum toxin type A based on severity of palmar hyperhidrosis.

Authors:  Keiko Ito; Takeshi Yanagishita; Yuichiro Ohshima; Yasuhiko Tamada; Daisuke Watanabe
Journal:  J Dermatol       Date:  2011-05-04       Impact factor: 4.005

Review 7.  Treatment of hyperhidrosis with botulinum toxin.

Authors:  Melissa A Doft; Krista L Hardy; Jeffrey A Ascherman
Journal:  Aesthet Surg J       Date:  2012-02       Impact factor: 4.283

8.  Repeated botulinum toxin type A injections to treat patients with Frey syndrome.

Authors:  Remco de Bree; Jeff E Duyndam; Dirk J Kuik; C René Leemans
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-03

9.  Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk.

Authors:  Won Oak Kim; Hae Keum Kil; Kyung Bong Yoon; Ko Un Noh
Journal:  Dermatol Surg       Date:  2009-03-30       Impact factor: 3.398

10.  Botulinum toxin type B for treatment of axillar hyperhidrosis.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Reiner Benecke
Journal:  J Neurol       Date:  2002-12       Impact factor: 4.849

View more
  3 in total

1.  [Hyperhidrosis-aetiopathogenesis, diagnosis, clinical symptoms and treatment].

Authors:  J Wohlrab; B Kreft
Journal:  Hautarzt       Date:  2018-10       Impact factor: 0.751

2.  [Botulinum toxin in dermatology].

Authors:  W G Philipp-Dormston
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

Review 3.  Dermatological problems of the puberty.

Authors:  Beata Bergler-Czop; Ligia Brzezińska-Wcisło
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.